公开(公告)号：US20130295179A1

公开(公告)日：2013-11-07

申请号：US13862179

申请日：2013-04-12

Applicant: Christian TERREAUX ,  Eleonora HOMBERGER ,  Burkhard KRIWET ,  Eduardo BARRAGAN PEREZ

Inventor： Christian TERREAUX ,  Eleonora HOMBERGER ,  Burkhard KRIWET ,  Eduardo BARRAGAN PEREZ

IPC: A61K31/202 ,  A61K33/26 ,  A61K33/30 ,  A61K31/4458 ,  A61K45/06

CPC classification number: A61K31/202 ,  A23L33/105 ,  A23L33/12 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/4458 ,  A61K31/519 ,  A61K31/59 ,  A61K31/675 ,  A61K31/714 ,  A61K33/26 ,  A61K33/30 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/322 ,  A23V2250/156 ,  A23V2250/1626 ,  A23V2250/1642 ,  A23V2250/1868 ,  A23V2250/187 ,  A23V2250/1874 ,  A23V2250/2132 ,  A23V2250/70

Abstract: The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine. The present application also relates to the method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising administering an effective amount of a composition comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.

公开(公告)号：US20130230592A1

公开(公告)日：2013-09-05

申请号：US13862142

申请日：2013-04-12

Applicant: Christian TERREAUX ,  Eleonora HOMBERGER ,  Burkhard KRIWET ,  Anne ECKERT

Inventor： Christian TERREAUX ,  Eleonora HOMBERGER ,  Burkhard KRIWET ,  Anne ECKERT

IPC: A61K31/202 ,  A61K31/355 ,  A61K31/714 ,  A61K31/59 ,  A61K31/675 ,  A61K31/519

CPC classification number: A61K31/202 ,  A23L33/105 ,  A23L33/12 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/4458 ,  A61K31/519 ,  A61K31/59 ,  A61K31/675 ,  A61K31/714 ,  A61K33/26 ,  A61K33/30 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/322 ,  A23V2250/156 ,  A23V2250/1626 ,  A23V2250/1642 ,  A23V2250/1868 ,  A23V2250/187 ,  A23V2250/1874 ,  A23V2250/2132 ,  A23V2250/70

Abstract: A composition for use in preventing and/or treating and/or reducing organic, including symptomatic, mental disorders, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least one vitamin selected from vitamin B6, folic acid, vitamin B12, vitamin E, and/or vitamin D, at least one mineral which is selenium and/or zinc, optionally other vitamins, and optionally a polyphenolic plant extract with antioxidant properties.

Abstract translation: 一种用于预防和/或治疗和/或减少有机（包括症状性精神障碍）的组合物，其包含：a）二十二碳六烯酸（DHA）和/或其药学上可接受的衍生物和/或前体; b）二十碳五烯酸（EPA）和/或其药学上可接受的衍生物和/或前体; c）γ-亚麻酸（GLA）和/或其药学上可接受的衍生物和/或前体; 以及选自维生素B6，叶酸，维生素B12，维生素E和/或维生素D中的至少一种维生素，至少一种硒和/或锌矿物，任选的其它维生素，以及任选的具有抗氧化性质的多酚植物提取物 。